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Portable oxygen concentrators (POC) are highly desirable for patients with lung disease trav-
eling by airplane, as these devices allow theoretically much higher travel times if additional
batteries can be used. However, it is unclear whether POCs produce enough oxygen in
airplanes at cruising altitude, even if complying with aviation regulations.
We evaluated five frequently used POCs (XPO2 (Invacare, USA), Freestyle (AirSep C., USA),
Evergo (Philipps Healthcare, Germany), Inogen One (Inogen, USA), Eclipse 3 (Sequal, USA)) at
an altitude of 2650 m (as simulated airplane environment) in 11 patients with chronic obstruc-
tive lung disease (COPD) and compared theses POCs with the standard oxygen system (WS120,
EMS Ltd., Germany) used by Lufthansa.
Oxygen was delivered by each POC for 30 min to each patient at rest, blood gases were
then drawn from the arterialized ear lobe. All POCs were able to deliver enough oxygen to
increase the PaO2 of our subjects by at least 1.40 kPa (10 mmHg). However, to achieve this
increase, the two most lightweight POCs (Freestyle and Invacare XPO2) had to be run at
their maximum level. This causes a significant reduction of battery life. The three other
POCs (EverGo, Inogen One, Eclipse 3) and the WS120 were able to increase the PaO2 by more(R. Fischer).
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148 R. Fischer et al.than 2.55 kPa (20 mmHg), which provides extra safety for patients with more severe basal
hypoxemia.
When choosing the right oxygen system for air travel in patients in COPD, not only weight,
but also battery life and maximum possible oxygen output must be considered carefully.
ª 2012 Elsevier Ltd. All rights reserved.Thenumber of patientswith lungdiseases is increasingand so
is the number of people with impaired lung function wanting
to travel by airplane. However, liquid oxygen is prohibited
during air travel and standard compressed oxygen steel
cylinders with oxygen-conserving devices allow only rela-
tively short travel time. For these reasons portable oxygen
concentrators (POC) are highly desirable, as these devices
allow theoretically much higher travel times if additional
batteries can be used. Before a POC can be used during air
travel three main questions need to be answered:
1.) Does the POC comply with aviation regulations?
2.) Does the POC produce enough oxygen at altitudes up to
2500 m? and
3.) Does the POC deliver enough oxygen for patients with
impaired lung function in an in-flight situation?
The first question is generally answered by the flight
authorities and depends mostly on compliance with radio
frequency unresponsiveness. The POCs approved by the
federal aviation administration (FAA) of the United States
can be found at the FAA website.1 All POCs tested in this
study are commonly used in Germany (Invacare XPO2
(Invacare, Elyria, Ohio), Freestyle (AirSep C., Buffalo, New
York), Evergo (Philipps Healthcare, Hamburg, Germany),
Inogen One (Inogen, Goleta, CA), Eclipse 3 (Sequal, Ball
Ground, GA)) and were FAA approved.
The second question was evaluated during a technical
test performed in Hintertux, Austria at four different alti-
tudes (1500 m, 2100 m, 2605 m and 3250 m). For the test,
each POC was connected to an artificial lung system
(ASL5000, IngMar Medical Ltd, Pennsylvania, USA) with
a flow analyzer (PF300, imtmedical Corp., Buchs,
Switzerland) and easyControl with easyLeak and HME-
sensor (SBM-Technology Corp., Wolfratshausen, Germany).
To compare the effectiveness of the POCs with a “gold
standard”, we tested the portable oxygen demand system
WS120 (compressed oxygen carbon cylinder with 300 bar
and an oxygen conserving device, EMS Ltd., Mo¨hrendorf,
Germany) used by Lufthansa for in-flight oxygen delivery
for flights up to 14 h.
All POCs maintained an oxygen concentration above 94%
up to the highest altitude tested (WS120 delivered 100%
oxygen). However, the delivered oxygen bolus was strongly
reduced when the POCs were used at higher altitudes (see
Table 1). Unfortunately, the Invacare XPO2 could not be
tested, as oxygen delivery was not stable enough to be
measured by the artificial lung system.
The third question was addressed during a study with
simulated in-flight conditions. The POCs were compared
with the system currently used by Lufthansa (WS120).
We selectedpatientswith chronic obstructive lung disease
(GOLD stage II/III) in a stable condition from our outpatient
clinic. Theywere studied at the Schneefernerhaus at 2650m.This altitude is comparable to the environment in an airplane
at cruising altitude.2 The local ethics committee approved
the study andwritten informed consentwas obtained fromall
participants.
Baseline evaluation was performed in Munich at an
altitude of 540 m and included medical history, spirometry,
bodyplethysmography, oxygen saturation, heart rate and
capillary blood gases from the arterialized ear lobe.
The patients were brought by cogwheel train to the
altitude lab at 2650 m, where they were connected to the
reference oxygen system used by Lufthansa during air
travel (WS120) delivering an equivalent of 2.8 l O2/min via
nasal cannula. After 30 min resting in supine position, blood
gases were sampled from the arterialized ear lobe.
Then, each patient received oxygen via nasal cannula from
one of the POCs. The oxygen delivery rate was chosen
according to the results of the technical test to obtain
approximately comparable delivery rates of 2.0e2.5 l O2/min.
The devices were then changed in a random order. We ob-
tained blood gas results and oxygen saturation data from each
patient after a steady state period of 30minwith each device.
To evaluate the improvement in oxygenation by the devices,
each patient was also tested after exposure to room air for
30 min.
During the study period, patients were not allowed any
exercise except for the walk to the bathroom, and
measurements were only taken after at least 10 min of rest.
Eleven patients (eight male, three female) were
included in the study. Mean FEV1 at baseline in Munich at an
altitude of 540 m was 48.3% predicted (range 35%e64%).
Baseline SaO2 was 94.8  1.8%, all patients were in stable
condition throughout the study period. The results of the
measurements at 2650 m are shown in the Table 1.Discussion
Although several companies claim that their POCs can be
used during air travel, testingwith patients under simulated,
realistic in-flight conditions has not been performed
systematically. One study was performed in a hypobaric
chamber testing POCs in patients with chronic obstructive
lung disease (COPD). The use of the FreeStyle (AirSep Corp.,
Buffalo, NewYork) resulted in a lower oxygenation compared
to continuous flow oxygen via compressed gaseous oxygen
with or without an oxygen-conserving device.3
In our study all POCs delivered enough oxygen to
increase the PaO2 of our subjects by at least 1.40 kPa
(10 mmHg). We chose a difference of 10 mmHg to ensure
that the change of pO2 was meaningful, as repeated
measurements of pO2 from an arterialized ear lobe sample
have been found to differ by a mean of 0.99  0.63 mmHg
and reflect arterial pO2 with a mean difference of
0.95  3.05 mmHg.4 However a patient would need to test
Table 1 Results of the blood gas measurements at 2650 m and technical data at 2605 m in different POCs and the WS120.
Room air
(at 2650 m)
Freestyle
(Airsep)
XPO2
(Invacare)
Inogen One
(Inogen)
EverGo
(Philipps)
Eclipse 3
(Sequal)
WS120 (EMS)
PO2 (kPa) 6.93  0.74 8.33  0.89 8.50  1.01 9.48  0.98 9.58  1.17 9.59  1.40 9.54  1.12
PCO2 (kPa) 4.97  0.56 5.03  0.61 4.96  0.81 4.99  0.68 5.20  0.53 5.12  0.55 5.15  0.68
pH 7.4  0.02 7.4  0.02 7.4  0.03 7.4  0.03 7.4  0.03 7.4  0.03 7.4  0.02
SaO2 (%) 84.9  5.3 90.9  2.6 91.5  2.9 93.3  2.5 93.7  1.9 93.5  2.1 93.9  2.8
Actual level/max.
possible level
e 3/3 4/5 4/5 4/6 3/6 0.7/1.5
Min. O2-Bolus (ml) e 7.9 na 7.6 7.5 11.2 25.2
Max. O2-Bolus (ml) e 16.7 na 39.8 38.4 67.4 75.1
Max. O2-concentration
(%)
e 94.6 na 94.1 93.2 94.7 99.9
Weight (kg) e 2.0 2.9 3.2 3.9 8.1 4.5
Weight of additional
battery (kg)
e 0.8 0.6 1.3 0.7 1.5 e
Treatment time (h)
at actual level
e 2 2.17 2.4 3.1 3.5 14
Treatment time (h)
with add. battery
4 4.28 4.8 6.2 7 e
Data of PaO2, PaCO2, pH, SaO2 are presented as mean  standard deviation; na denotes not available due to the failure in the technical
test. Actual level was the level used at the Schneefernerhaus at 2650 m.
Comparison of POCs simulated airplane environment 149his or her personal oxygen demand according to guidelines
to ensure clinical usefulness.5
To achieve this increase, the two most lightweight POCs
(Freestyle and InvacareXPO2)had tobe runat theirmaximum
level, as they contain less zeolite to absorb the atmospheric
nitrogen, thus reducing the oxygen concentrating capacity.
This causes a significant reduction of battery lifewhichwould
necessitate additional battery packs adding to the weight
carried during intercontinental flights. These POCs could be
recommended only in patients with less impaired lung func-
tion as effective oxygen delivery is markedly reduced
compared to the other three POCs or the WS120.
The three other POCs and the WS120 increased the PaO2
by more than 2.55 kPa (20 mmHg). This provides extra
safety for patients with more severe basal hypoxemia to
maintain a minimum in-flight PaO2 of 7 kPa (50 mmHg) as
recommended by current guidelines.5
However, the weight of these stronger POCs with the
additional batteries is an important consideration limiting
their use for air travel, when any additional weight might
further reduce the mobility of already impaired patients.
In contrast to the POCs, the WS120 delivers oxygen
independent from atmospheric pressure with a stable and
precisely adjustable output. However, the overall duration
is limited by the capacity of the oxygen cylinders which last
in general for 14e18 h. In addition, many airlines charge
between 50 and 300 Euro per flight segment, if oxygen
supply is required.6 Compared with these costs, renting of
portable oxygen concentrators for e.g. 20 days is much
cheaper (appr. 250 Euros).
In conclusion, our study showed that not every POC
delivers a comparable oxygen output at an altitude
comparable to the in-flight environment, and we found
substantial differences in weight and possible duration of
use. The noise level emitted by the POCs may be considered
as disturbing. Therefore, the choice of the specific type ofoxygen supply during air travel remains an individual pref-
erence. Our data may help in choosing the right system.
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